Podcasts about Pharma

Can artificial intelligence redefine the future of drug development and clinical trials?  In this episode of Tech Talks Daily, I sit down with Dave Latshaw, Ph.D., the internationally recognized AI and machine learning expert who serves as CEO of BioPhy. Founded in 2019, BioPhy focuses on using AI to revolutionize the later stages of drug development, a critical yet often overlooked segment of the pharmaceutical pipeline. Dave shares insights into BioPhy's innovative platform, which combines scientific, clinical, and regulatory insights to predict clinical trial success and steer capital allocation. At the heart of BioPhy's approach is its patent-pending AI engine, BioLogic, and generative AI solution, BioPhyRx, designed to enhance clinical trial outcomes, reduce failure rates, and accelerate the time to market for life-saving drugs. Dave also explores how BioPhy's operational assessment model prioritizes immediate ROI by addressing challenges downstream from drug discovery. In our conversation, Dave delves into the complexities of AI adoption in pharma, including the challenges of scaling AI solutions, managing high computational costs, and overcoming stakeholder fears about job displacement. Drawing from his experience at Johnson & Johnson, where his AI innovations contributed to the global rollout of the COVID-19 vaccine, Dave reflects on lessons learned and the transformative potential of AI in healthcare. As we look ahead, Dave discusses the future of AI in reducing administrative burdens on clinicians, automating regulatory compliance, and enabling groundbreaking advancements like DeepMind's AlphaFold.  How can AI transform not just how we develop drugs but also the healthcare outcomes for millions of people worldwide? Tune in to find out, and share your thoughts on the role of AI in the future of medicine.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Former executives of MyoKardia have launched a new biotech company called Kardigan with $300 million in funding, aiming to make cardiovascular disease curable and preventable. In other news, Pfizer's subcutaneous PD-1 blocker has shown success in a phase III trial for bladder cancer, potentially providing a new treatment option. Lilly has partnered with venture capital firm Andreessen Horowitz on a $500 million fund for early-stage biotech companies. However, the Healey ALS trial involving Denali Therapeutics, AbbVie, and Calico Life Sciences has faced setbacks, highlighting challenges in developing treatments for amyotrophic lateral sclerosis. Updates in the biopharma industry include Lilly's investments in IPF treatments, rising costs of Part D drugs, and layoffs at companies like IGM Biosciences, Shoreline, and Intellia. Verdiva has entered the obesity market with a $410 million debut. Job opportunities in the biopharma sector include positions at Biomarin Pharmaceutical, Avidity Biosciences, AbbVie, and Moderna Inc.

In this episode, Frederik explores the role of public procurement in decarbonizing the healthcare sector.He talks about the need for standardized sustainability requirements and shares insights from a survey with buyers across Europe. He also delves into the progress of the pharmaceutical industry and the importance of weighted tender scoring criteria.Tune in to learn more about the importance of sustainability in healthcare procurement and the need for greater alignment between ambitions and execution.

Die erste AOM Shorts Folge im Jahr 2025 ist da und Host Florian Vette und MOVESELL Marketplace Experte Ole Schleth starten direkt mit spannenden Auswerteungen und Updates ins neue Jahr. Seit einem Jahr gibt es TikTok Shop in den USA und schon jetzt ist der US Markt der zweit größte Markt für TikTok. Wie entwickelte sich TikTok Shop in anderen Ländern und wann wird TikTok Shop in Deutschland gelauncht? Außerdem analysiert Florian die erfolgreichsten Händler des Weihnachtsgeschäfts in Frankreich. Besonders spannend: Amazon liegt in der Kategorie Bekleidung auf Platz eins. Wo liegt Amazon in den Kategorien Home, Pharma und DIY und welche Marktplätze sind hier jeweils die größte Konkurrenz? Amazon startet mit einer ganzen Reihe an Updates und News ins neue Jahr: Mit dem neuen Amazon Retail Ad Service können Marken Sponsored Ads auf externen Websites und Apps platzieren. Für wen ist der neue Service zugänglich und warum ist das nicht nur für Advertiser sondern auch für die externen Plattformen sehr spannend? Ole berichtet außerdem über eine Erweiterung der Amazon Advertising Console, die eine detaillierte Customer-Journey-Analyse ermöglicht und von einer neuen Targeting-Option zur gezielten Ansprache von Amazon-Business-Kunden. Abschließend gibt Ole allen Amazon Sellern und Amazon Vendoren einen besonders wichtigen Hinweis: Die aktualisierten Anforderungen für Produkttitel sorgen für akuten Handlungsbedarf. Was ändert sich und wie sollten Vendoren und Seller nun reagieren?

In this episode, Nathaniel Mead—epidemiologist, public health researcher, and science editor—delivers an eye-opening account of censorship in scientific publishing. Drawing from decades of experience, including his time on the editorial board of Integrative Cancer Therapies, Nathaniel examines the increasing influence of pharmaceutical companies and the retraction of critical research, including studies questioning the safety of COVID-19 vaccines. Nathaniel's insights reveal the struggles scientists face when challenging dominant narratives and the long-term impact on medical research and public trust. Discover: How are retractions being used as tools of suppression. What role does pharmaceutical influence play in shaping journal publications. How does censorship affect public trust and the future of research ethics. Why is a new system for scientific publishing vital to maintaining free inquiry. If you've ever wondered about the hidden challenges behind scientific publishing or questioned the impartiality of medical research, this episode offers thought-provoking perspectives and actionable solutions. Curious to learn more about Nathaniel's experiences and advocacy for change? Click here to dive deeper into his impactful work! Episode also available on Apple Podcasts: https://apple.co/38oMlMr

In this Evolutionary.org Underground Podcast for iTunes episode your hosts Stevesmi and Da Mobster from the UK Iron Den discuss – Top steroid cycles for those under 30 years old by Para Pharma • The science behind male sexual development • Risks of side effects in the under age 30 user • Our choice of the best Para-Pharma orals and doses • Which of the best Para-Pharma injectables and doses for under 30 • Why we love Para-Pharma Link to articles: https://www.evolutionary.org/steroids/ Link to the Evolutionary threads discussing steroid cycles (note ages) 1. https://www.evolutionary.org/forums/threads/how-to-lean-out-from-steroids.102583/ 2. https://www.evolutionary.org/forums/threads/steroid-cycle-for-more-gains.101993/ 3. https://www.evolutionary.org/forums/threads/how-to-approach-my-next-steroid-cycle.102178/ 4. https://www.evolutionary.org/forums/threads/first-cycle-steroid-help-europe-happy-new-year.102589/ 5. https://www.evolutionary.org/forums/threads/when-you-get-older-steroid-help.101894/ For 1-on-1 coaching/consultation/source help start a conversation by contacting Stevesmi at: https://www.elitefitness.com/forum/members/stevesmi.219851/ or https://www.evolutionary.org/forums/members/stevesmi.85/ Where to get blood tests: https://www.evolutionary.org/forums/source-talk/bloodwork-private-md-5695.html Please note we're not doctors and the opinions are ours. It's our view and is based on our experience and views on the topic. Our Podcasts are for informational purposes and entertainment only. The Freedom of speech and 1st amendment applies.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Ian Tzeng, a Managing Director and Partner in L.E.K. Consulting. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Ian, covering: Reflections on 2024's market dynamics, shifting sponsor behavior, big pharma woes, biotech rebound and segment-specific impact The outlook for 2025 across discovery, development, clinical trials, and manufacturing The uptick Ian expects and where companies should be focusing efforts Ian Tzeng, a Managing Director and Partner in L.E.K.'s Boston office, joined the company in 1998 with experience in growth strategy, regulated markets, innovation, pricing, and mergers and acquisitions. He focuses on healthcare and life sciences, including pharmaceuticals, vaccines and medical devices.    He leads L.E.K.'s Pharmaceutical Contract Services practice, including CROs, CDMOs, supply chain and distribution, commercial, medical, and market access services. Other areas of deep experience include rare diseases, biodefense, biosimilars and generics, and consumer-directed healthcare.  Additionally, Ian has extensive consulting and board experience with nonprofit organizations in education, arts, LGBT advocacy and public service. He received a Bachelor of Arts degree, magna cum laude, in chemistry from Harvard College and is a George F. Baker Scholar, Master of Business Administration with high distinction from Harvard Business School.   Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!   Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.  

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Verdiva has entered the competitive obesity market with a $410 million debut, focusing on next-generation therapies. The company's lead asset is an oral glp-1 receptor agonist that can be dosed weekly, aiming to improve accessibility and affordability. In 2024, the biopharma industry saw a significant increase in first-time VC funding, totaling $7.7 billion over 137 deals. J.P. Morgan predicts a strong year for biopharma in 2025, with an uptick in M&A activity and FDA decisions to watch. The FDA has proposed setting a bar for weight-loss therapies as the obesity space heats up. Lilly has won Medicare coverage for Zepbound in sleep apnea, while Vanda criticizes the FDA's conduct after a drug rejection. Layoffs have affected the gene therapy space, with companies like Resilience and Scribe cutting staff. Overall, the outlook for biopharma in 2025 is cautiously optimistic, with opportunities for innovation and growth.

In this Evolutionary.org Underground Podcast for iTunes episode your hosts Stevesmi and Da Mobster from the UK Iron Den discuss – Top Training and Nutrition 'Bro science' myths by Euro Pharma • A brief explanation of what Bro-Science is • Three Examples of training bro-science • Three more examples of nutrition myths. • Why having sources like Euro-Pharma products can be trusted • Why Euro-Pharma is regarded so highly Link to articles: https://www.evolutionary.org/category/pc-bodybuilding/workouts/ Link to the Evolutionary threads discussing bro-science and training 1. https://www.evolutionary.org/forums/threads/eq-and-test-easy-stack.89461/post-1342352 2. https://www.evolutionary.org/forums/threads/hellen-fits-30-day-cutting-program-log.79689/post-1159682 3. https://www.evolutionary.org/forums/threads/lifting-heavy-while-fasted.59576/post-938700 4. https://www.evolutionary.org/forums/threads/steroid-rage.44573/post-802925 5. https://www.evolutionary.org/forums/threads/bodybuilding-spirituality.6102/post-111904 aSXDCFGH For 1-on-1 coaching/consultation/source help start conversation by contacting Stevesmi at: https://www.elitefitness.com/forum/members/stevesmi.219851/ or https://www.evolutionary.org/forums/members/stevesmi.85/ Where to get blood tests: https://www.evolutionary.org/forums/source-talk/bloodwork-private-md-5695.html Please note we're not doctors and the opinions are ours. It's our view and is based on our experience and views on the topic. Our Podcasts are for informational purposes and entertainment only. The Freedom of speech and 1st amendment applies.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Galapagos is set to split into two entities by mid-2025, creating a new innovative medicines specialist and a cell therapy company. Novo has invested $4.6 billion to expand its deal with Valo, aiming to maintain leadership in the cardiometabolic space. Tenvie, supported by venture partners, will be focusing on developing brain-penetrant small molecules for neurological and metabolic diseases.The trend of licensing deals in the pharmaceutical industry is on the rise, with experts debating whether it is a sign of desperation or a crucial part of the biotech ecosystem. Roche is in the final stages of acquiring Poseida for up to $1.5 billion, while Cassava has had to lay off a third of its staff following a setback in an Alzheimer's drug trial. Major pharmaceutical companies are looking towards China for potential deal opportunities, despite regulatory uncertainty in the region. The FDA is considering setting a bar for weight-loss therapies as the obesity space continues to heat up. Looking ahead to 2025, there is a cautiously optimistic outlook for the biopharma industry, with predictions of increased M&A activity leading up to key events like the J.P. Morgan Healthcare Conference and important FDA decisions.As licensing deals become more common in the biotech industry, big pharma companies are exploring partnerships in China. The industry is gearing up for the J.P. Morgan Healthcare Conference with a sense of uncertainty after M&A activity did not meet expectations in 2024. Biospace's NextGen Class of 2025 features startups focusing on emerging trends in biopharma, attracting investments from major players.Companies like Roche, Merck, and Novo are making significant moves in the biopharma space, shaping the industry landscape. Job opportunities are available in various sectors, including positions like Chief of Staff and Senior Director in IT and Translational Neuroscience. Biospace is working on enhancing user experience by personalizing emails based on individual preferences.Thank you for tuning in to Pharma and Biotech Daily, where we bring you the latest updates and insights from the world of pharmaceuticals and biotechnology.

In this episode of the 21 Min Pharma Edge powered by Game of Pharma, we sit down with Ashok Bhatia, former President - Emerging Markets at Zydus Lifesciences, to explore his remarkable 48-year journey in the pharma industry.From starting as an Assistant Chemist to becoming a leader in global markets, Mr. Ashok shares invaluable insights into: The evolution of pharma marketing over the decades. Overcoming challenges without digital tools in the early days. The art of brand building and creating sustainable profits. Defining moments that shaped his legacy in the industry.Mr. Ashok's journey is a testament to hard work, innovation, and staying true to the basics while pushing boundaries.Whether you're a pharma professional, marketer, or someone passionate about leadership, this episode is packed with inspiration and actionable lessons. Don't miss this inspiring conversation! Follow to the Game of Pharma podcast for more exclusive interviews with pharma industry leaders.Available on Spotify, Gaana, JioSaavn, Amazon Music, and Apple Podcasts.Mr. Ashok Bhatia's LinkedIn: https://www.linkedin.com/in/ashok-bhatia-6079a239/Host's LinkedIn: https://www.linkedin.com/in/lokesh-sharma-7250a71a9/Visit our website for the latest updates in pharma and to stay informed about future episodes: https://gameofpharma.inFollow us on social media-Instagram: https://www.instagram.com/gameofpharma/LinkedIn: https://www.linkedin.com/company/game-of-pharma/YouTube: https://www.youtube.com/channel/UCGLNWWSCYZz3WbY77gencpw

WEBSITE: https://www.nogreyareaspodcast.com/INSTAGRAM: https://www.instagram.com/nogreyareas_gagliano/FACEBOOK: https://www.facebook.com/NoGreyAreasTIK TOK: https://www.tiktok.com/@nogreyareasgaglianoEMAIL: info@nogreyareas.comYOUTUBE: https://www.youtube.com/channel/UCbnC2rjEumGJhqy54qazFFwA new year means new possibilities. How about a new year focused on a better, happier, healthier you? In our very first episode of 2025, Dr. Melody Rodarte, a board-certified obesity and internal medicine specialist, brings her expertise in holistic and preventative medicine to help listeners jumpstart their wellness and health goals for the new year. From the importance of prioritizing sleep, exercise, and nutrition, to recognizing food as both medicine and potential poison, Dr. Rodarte covers practical, manageable ways to build healthier habits that last. With two-thirds of Americans facing obesity and a healthcare system often driven by insurance codes, Dr. Rodarte shares her passion for patient-focused care and the steps everyone can take to regain control of their well-being. She faces the red flags of the healthcare industry, including the big Pharma ideals, weight loss fad diets, and the craze about GLP-1.Dr. Rodarte also dives into the role of personalized medicine and the vital importance of hormones for both men and women as we age. For listeners ready to explore a new approach to health, this episode is packed with tangible steps for achieving your health and fitness goals for 2025. Stay tuned for our part 2 wellness in 2025 episode series dropping in 2 weeks! Remember, this year isn't about a brand-new you—it's about becoming a better, stronger, and healthier version of you!No Grey Areas is a motivational podcast with captivating guests centered around how our choices humanize, empower, and define who we become. This podcast is inspired by the cautionary tale, No Grey Areas, written by Joseph Gagliano. Learn more about the truth behind his story involved with sports' biggest scandal at https://www.nogreyareas.com/

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in the Pharma and Biotech world. ## Pfizer announces positive results for COVID-19 vaccinePfizer has announced positive results for its COVID-19 vaccine, with an efficacy rate of over 90%. This is a promising development in the fight against the global pandemic.## Moderna receives FDA emergency use authorization for COVID-19 vaccineModerna has received FDA emergency use authorization for its COVID-19 vaccine. This is another step forward in the efforts to combat the spread of the virus.## Johnson & Johnson vaccine shows promising results in early trialsJohnson & Johnson's COVID-19 vaccine has shown promising results in early trials, with a single-dose option being tested. This could potentially streamline the vaccination process.## AstraZeneca faces setbacks in COVID-19 vaccine productionAstraZeneca has faced setbacks in the production of its COVID-19 vaccine, leading to delays in distribution. This highlights the challenges of scaling up production to meet global demand.## Novartis announces acquisition of The Medicines CompanyNovartis has announced the acquisition of The Medicines Company in a deal worth over $9 billion. This strategic move will expand Novartis' portfolio in the cardiovascular space.## Roche launches new diagnostic test for Alzheimer's diseaseRoche has launched a new diagnostic test for Alzheimer's disease, which aims to detect the disease at an earlier stage. This could lead to improved outcomes for patients.## Gilead Sciences receives FDA approval for new HIV treatmentGilead Sciences has received FDA approval for a new HIV treatment, expanding options for patients living with the virus. This demonstrates ongoing innovation in the field of infectious diseases.## Merck announces positive results for cancer immunotherapy drugMerck has announced positive results for its cancer immunotherapy drug, showing promising efficacy in treating certain types of cancer. This represents a significant advancement in oncology research.## Sanofi partners with Translate Bio on mRNA vaccinesSanofi has partnered with Translate Bio to develop mRNA vaccines for infectious diseases, including COVID-19. This collaboration leverages cutting-edge technology to address global health challenges.

Jeff Berg, president of AbelsonTaylor Group, offers an independent's perspective on last year's announced merger of Omnicom with Interpublic Group, in an interview with Jack O'Brien.And on our Trends segment, Marc Iskowitz previews the 43rd annual J.P. Morgan Healthcare Conference, kicking off next week in San Francisco. Tune in, as well, for a big reveal involving the brand's spring conference, MM+M Transform, coming up on April 3, 2025, in New York City.Music by Sixième Son Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.

In this revealing episode, Tina Anderson exposes the dark side of pharmaceutical practices and their effects on our health. Learn about the industry's aggressive influence on medication prescriptions.   Discover the crucial link between gut health and overall wellness. Tina explains how substances like antibiotics and glyphosate harm our gut microbiome, impacting everything from immunity to mental health.   Tina shares practical tips for nurturing your gut health through diet diversity, effective probiotics, and lifestyle adjustments. Find out how to build a resilient digestive system that supports your overall health.   In This Episode:   00:00 Pharmaceutical Industry Insights 01:31 The Importance of Gut Health 02:36 Interview with Tina Anderson 05:01 Tina's Journey from Pharma to Natural Health 09:37 Understanding the Gut Microbiome 14:54 Challenges to Gut Health 22:55 The Importance of Immunoglobulins in Colostrum 25:44 The Benefits of Probiotics and Spore-Based Bacteria 33:46 The Role of Vitamin K2 in Health 39:44 Strategies for Supporting Gut Health 44:16 Final Thoughts and Resources     Struggling with low energy, frequent colds, or dull skin? Vitamin C is essential for boosting your immune system and revitalizing skin health. Paleo Valley's Essential C Complex, made from potent whole food sources, ensures you get these benefits naturally, without synthetic additives.   Enjoy a special 15% discount on your first order of Paleo Valley's Essential C Complex by visiting PaleoValley.com/Jockers. Harness the power of nature with this whole food supplement to support your health effectively.   Kick off the new year by supercharging your gut health with Just Thrive Probiotic! Unlike ordinary probiotics that perish before they even reach your gut, Just Thrive's revolutionary formula is clinically proven to arrive 100% alive. This ensures optimal digestive health, robust immunity, and vibrant energy—essential components for anyone aiming to conquer their wellness goals this year.   Perfect for supporting effortless weight management, Just Thrive Probiotic is your go-to for a healthier lifestyle. Don't wait to start feeling your best—head over to justthrivehealth.com and use code Jockers to snag a 20% discount on your first purchase. Here's to a healthier, happier you with Just Thrive! Unlock the secrets of your body's unique nutritional needs with Genova Connect's Metabolomix Plus, an easy at-home test that dives deep into your metabolism. This comprehensive assessment reveals critical insights into your amino acids, vitamins, antioxidants, and fatty acids levels, guiding you to optimize your diet and supplements with precision. Ready to revolutionize your health? Visit GenovaConnect.com to discover how you can fine-tune your nutrition for peak performance and vitality     “Our gut microbiome is really dictating virtually all aspects of our overall health."  - Tina Anderson     Subscribe to the podcast on: Apple Podcast Stitcher Spotify PodBean  TuneIn Radio     Resources: Visit justthrivehealth.com and use code Jockers for a 20% discount Paleovalley - visit paleovalley.com/jockers Visit GenovaConnect.com   Connect with Tina Anderson: https://www.instagram.com/justthrivehealth   Connect with Dr. Jockers: Instagram – https://www.instagram.com/drjockers/ Facebook – https://www.facebook.com/DrDavidJockers YouTube – https://www.youtube.com/user/djockers Website – https://drjockers.com/   If you are interested in being a guest on the show, we would love to hear from you! Please contact us here! - https://drjockers.com/join-us-dr-jockers-functional-nutrition-podcast/  

TODAY ON THE ROBERT SCOTT BELL SHOW: Bird Flu Death, Mike Colomb, Private Membership Associations, Mysterious Fog Sickness, Antibiotic Crisis Looms, Meta Ends Fact-Checking, Pharma Funds Trump, Lead in Baby Food and MORE! https://robertscottbell.com/bird-flu-death-mike-colomb-private-membership-associations-mysterious-fog-sickness-antibiotic-crisis-looms-meta-ends-fact-checking-pharma-funds-trump-fda-limits-lead-in-baby-food/

Welcome back for the first show of the year! There's been a lot of moving parts this off season and the Pharma Boys have it covered. Thanks for listening!

In this episode, host Dr. Alexandria Wise sits down with Dr. Najat Khan, Chief R&D Officer and Chief Commercial Officer at Recursion Pharma, live from the floor of CNS Summit 2024. Together, they explore how cutting-edge technologies like AI and machine learning are transforming drug discovery and development, shortening timelines, and driving precision medicine.Dr. Khan shares her inspiring journey, from her upbringing surrounded by medicine to leading innovations at the intersection of biology, chemistry, and technology. She emphasizes the importance of connecting the "first mile" of biological insight to the "last mile" of patient access and discusses Recursion's mission to decode biology and radically improve lives.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

In this Evolutionary.org Underground Podcast for iTunes episode your hosts Stevesmi and Da Mobster from the UK Iron Den discuss – Top steroid 'Bro science' myths by Euro Pharma • The meaning of the phrase Bro-Science • The reasons behind how people sometimes confuse Bro-Science with actual facts • We breakdown some classic PED examples of Bro-Science • How Euro-Pharmacies has put together great blends which work • Why Euro-Pharma is a well established supplier of PEDs Link to articles: https://www.evolutionary.org/nutrition/ Link to the Evolutionary threads discussing bro-science 1. https://www.evolutionary.org/forums/threads/losiols-road-to-pro-card-log.100360/post-1598447 2. https://www.evolutionary.org/forums/threads/my-trt-plus-tesamorelin-3-month-cycle-log.98610/post-1566846 3. https://www.evolutionary.org/forums/threads/how-to-truly-bulk-up-on-a-steroid-cycle.95524/post-1393523 4. https://www.evolutionary.org/forums/threads/hcg-during-a-cycle-with-oral-steroids-only.96667/post-1436426 5. https://www.evolutionary.org/forums/threads/my-current-aussie-cycle.89743/post-1348677 For 1-on-1 coaching/consultation/source help start conversation by contacting Stevesmi at: https://www.elitefitness.com/forum/members/stevesmi.219851/ or https://www.evolutionary.org/forums/members/stevesmi.85/ Where to get blood tests: https://www.evolutionary.org/forums/source-talk/bloodwork-private-md-5695.html Please note we're not doctors and the opinions are ours. It's our view and is based on our experience and views on the topic. Our Podcasts are for informational purposes and entertainment only. The Freedom of speech and 1st amendment applies.

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Merck has acquired a Wuxi Biologics facility in Ireland for $500 million, expanding manufacturing operations in the biopharma industry. Analysts predict Viking Therapeutics as a top candidate amid higher M&A activity. Danish biotech Orbis has secured $93 million in funding for developing oral medicines. Evidence is growing on the benefits of GLP-1s in treating heart disease beyond weight loss and blood sugar control. Lilly has opened a new facility to drive innovation in bringing medicines to market, while Novo has filed a citizen petition to block compounded Victoza. Roche has invested $1 billion for another ADC from China. Various job opportunities are available in the industry, with insights on Alzheimer's treatment, Novo vs. Lilly's performance, and updates on FDA decisions and lawsuits related to GLP-1 products.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Eli Lilly has requested to join a lawsuit against the FDA filed by compounding pharmacies, indicating the outcome could impact its business. Despite having inferior GLP-1 products, Novo Nordisk is outperforming Lilly due to superior marketing strategies. The pharmaceutical industry is seeing an increase in hiring for computational biology and data science roles. Regeneron's acquisition of Oxular has resulted in the elimination of the Oxular workforce.In other news, Roche has committed potential funding for an ADC from China, Neumora's depression drug failed in pivotal trials, and Sangamo's stock dropped as Pfizer ended a gene therapy pact. Job opportunities include positions in marketing, experimental medicine, external engagement, and congress meeting planning.

In this episode of BioTalk Unzipped, hosts Gregory Austin and Chad Briscoe welcome Dr. Nathan Teuscher, a seasoned expert in clinical pharmacology and pharmacometrics. The conversation explores Nathan's career journey, the innovative charity Light the World, and the transformative role of AI in drug development. They discuss the challenges and opportunities presented by AI, particularly in automating data analysis and rethinking traditional reporting methods in the pharmaceutical industry. The episode emphasizes the potential for small companies to leverage cloud-based tools and APIs to enhance efficiency and drive innovation in drug development. In this conversation, the speakers explore the intersection of data analysis, AI tools, and advancements in gene editing with organ transplants. Chapters 00:00 Episode Preview 00:55 Introduction to BioTalk Unzipped 02:06 Charity Spotlight: Light of the World 04:51 Nathan Teuscher's Career Journey 07:34 Differentiating AI Types in Life Science 12:41 Challenges with Large Language Models 15:39 Rethinking Reporting in Pharma 17:56 The Future of AI and Analytics in Pharma? 18:52 Leveraging APIs (Application Programming Interfaces) for Small Companies 23:05 Leveraging Data, AI, and APIs in 3 Dimensions 26:22 NEW NEWS! - Gene Editing Breakthroughs in Medicine How to reach us: Light the World Charity - Church of Jesus Christ Latter Day Saints https://www.churchofjesuschrist.org/comeuntochrist/light-the-world  Nathan Teuscher https://www.linkedin.com/in/nathanteuscher/  Aplos Analytics - https://aplosanalytics.com/  Nathan Teuscher's Podcast: Clinical Pharmacology Podcast https://teuschersolutions.com/  Collaboration with BioTalk Unzipped (Ep. 40) https://podcasts.apple.com/us/podcast/collaboration-with-biotalk-unzipped-ep-40/id1695617234?i=1000682122951  Dr. Chad Briscoe https://www.linkedin.com/in/chadbriscoe/  Celerion - https://www.celerion.com/   Gregory Austin https://www.linkedin.com/in/gregoryaustin1/  ECI - https://eci-rx.com /  Sound Bites "We don't need to write reports anymore." Takeaways Nathan Teuscher has over 20 years of experience in clinical pharmacology and pharmacometrics. Light the World charity offers unique giving machines for donations. AI can automate repetitive tasks in drug development, freeing up human capital for innovation. There are two types of AI: large language models and automated data analysis. Large language models can be unreliable in scientific contexts. Pharmaceutical companies spend significant resources on report writing, which may not add value. Small companies can leverage APIs to access standardized calculations and data analysis. The pharmaceutical industry is often insular, limiting the potential of AI. AI could potentially eliminate the need for extensive written reports in drug development. Collaboration and data sharing are crucial for advancing AI in the pharmaceutical industry. Leveraging data effectively requires combining various data sets and tools. The evolution of AI tools is crucial for navigating new technologies. Gene editing represents a significant breakthrough in organ transplantation. New News Story:  A woman in the US is the third person to receive a gene-edited pig kidney https://www.technologyreview.com/2024/12/17/1108905/a-woman-in-the-us-is-the-third-person-to-receive-a-gene-edited-pig-kidney/ Image Credits Pig Kidney, https://ny1.com/nyc/all-boroughs/news/2023/08/16/pig-kidney-works-in-a-donated-body-for-over-a-month--a-step-toward-animal-human-transplants  Keywords BioTalk, pharmacology, AI in pharma, drug development, pharmacometrics, software development, clinical research, Light the World, charity, data analysis, AI tools, gene editing, kidney transplant, pharmaceuticals, virtual trials, healthcare innovation, drug development, patient engagement, medical technology, drug dosage, oncology, FDA approval, cell therapy, immunocompromised, collaboration, success, clinical pharmacology, podcast, healthcare

Il y a cinq ans, la crise du Covid-19 rappelait au monde l'importance de la souveraineté sanitaire. Produire et même créer, concevoir localement des médicaments, mais aussi des dispositifs médicaux pour pouvoir soigner sa population en toute indépendance est devenu un idéal à atteindre. En Afrique, des entreprises et des pôles de recherches commencent à émerger. C'est notamment le cas au Maroc. De notre correspondant à Rabat,C'est dans la banlieue de Rabat que Moldiag a installé son unité de production. Et pour y accéder, il faut montrer patte blanche. « On n'a pas le droit de rentrer sans ça », explique le docteur Abdeladim Moumen, le fondateur et directeur scientifique de Moldiag. Des équipements de protection (blouses, charlottes…) qui répondent à des normes strictes. Ici, la start-up fabrique des kits de diagnostic. « C'est unique en Afrique. Nous sommes les premiers à maîtriser toutes les étapes, depuis le développement qui est 100% marocain, jusqu'à l'industrialisation et la commercialisation », explique-t-il.Quatre salles en enfilade communiquent grâce à des passe-plats pour éviter toute contamination. Le processus de production est précis, le résultat de dix ans d'expérience dans le domaine. « On a mis au point six tests, en comptant celui du Mpox. Ils sont validés cliniquement et autorisés pour la commercialisation. On a déjà commencé à les commercialiser d'ailleurs », détaille le docteur Abdeladim Moumen.Des solutions adaptées aux besoins du continentHépatite C, tuberculose, leucémie, Moldiag produit même, depuis peu, des tests PCR pour détecter le Mpox, qui ont été commandés par la RDC notamment. Un kit de diagnostic qui est parvenu à intégrer la liste des tests recommandés par l'Africa CDC, l'agence sanitaire de l'Union africaine, aux côtés de ceux mis au point par les grands laboratoires américains ou chinois.« Aujourd'hui, grâce à ces kits, on arrive à contribuer à la sécurité sanitaire de notre pays », se réjouit Nawal Chraibi, à la tête de Moldiag. Elle est aussi la directrice générale de la fondation MAScIR, un centre de recherches qui dépend de l'université Mohammed VI Polytechnique et qui a développé tous ces tests, permettant l'émergence de compétences locales.« On s'est rendu compte que les géants du diagnostic ne s'intéressaient pas forcément aux maladies qui touchent le continent africain », souligne la dirigeante. Atteindre la souveraineté sanitaire permettrait de répondre à ses besoins spécifiques, mais elle a un coût. « On ne peut pas faire de la recherche et investir dans les biotechnologies, les vaccins si notre marché est restreint, d'où la nécessité d'avoir un grand marché comme celui de l'Afrique. Le Maroc confirme actuellement sa volonté de devenir une plateforme de recherches sur le continent », analyse le docteur Hamdi Tayeb, chercheur en politiques et systèmes de santé. Aujourd'hui, l'Afrique importe encore 95% de ses médicaments et pratiquement tous ses vaccins.À lire aussiMaroc: le laboratoire Pharma 5, fleuron de l'industrie pharmaceutique africaine

Air Date 1/4/2025 The murder of a health insurance CEO being met with widespread approval and the risk of going backward on life-saving vaccines pretty much sums up the current state of our approach to health care in this country. Be part of the show! Leave us a message or text at 202-999-3991 or email Jay@BestOfTheLeft.com Full Show Notes | Transcript BestOfTheLeft.com/Support (Members Get Bonus Shows + No Ads!) Join our Discord community! KEY POINTS KP 1: Weekly Roundup Luigi Mangione and the End of Civilization - Straight White American Jesus - Air Date 12-13-24 KP 2: You Don't Actually Need to Condemn the Murder of the CEO Guy - Serious Inquiries Only - Air Date 12-12-24 KP 3: The Dark History Behind RFK Jr.'s Health Policies - The Majority Report - Air Date 12-11-24 KP 4: Vaccine skepticism Will the new Trump admin axe the polio vaccine - The ReidOut - Air Date 12-13-24 KP 5: Weekly Roundup Luigi Mangione and the End of Civilization Part 2 - Straight White American Jesus - Air Date 12-13-24 KP 6: The Health Care Crisis Is The Democracy Crisis - The Lever - Air Date 12-17-24 (48:31) NOTE FROM THE EDITOR On the racist history of opposing universal health care DEEPER DIVES (53:28) SECTION A - RFK Jr. (1:07:08) SECTION B - Luigi Mangione (1:22:43) SECTION C - United Health Care (1:41:01) SECTION D - Health Care History SHOW IMAGE Description: A cropped photo of two people holding a handmade sign that says “Healthcare for people NOT for profit!” Credit: “Demand SINGLE PAYER Expanded & Improved Medicare for All HR 676 Now Protest” by Elvert Barnes, Flickr | License: CC BY-SA 2.0   Visit us at BestOfTheLeft.com Follow BotL: Bluesky | Mastadon | Threads | X

In this Evolutionary.org Underground Podcast for iTunes episode your hosts Stevesmi and Da Mobster from the UK Iron Den discuss – Model your bodybuilding goals - The benefits By Euro Pharma • What do we mean by 'model' • How the benefits of picking the right model • Modelling and how it applies to training, nutrition AND PED use • How Euro-Pharma enables you to model another's cycle identically • Why Euro-Pharma is one of the most highly regarded sources in the world today! Link to articles: https://www.evolutionary.org/category/pc-bodybuilding/workouts/ Link to the Evolutionary threads discussing support and Euro Pharmacies 1. https://www.evolutionary.org/forums/threads/testosterone-equipoise-trenbolone-cycle-log.96963/post-1512809 2. https://www.evolutionary.org/forums/threads/evolutionary-org-hardcore-2-0-9-getting-ripped-in-the-spring-euro-pharmacies.88402/ 3. https://www.evolutionary.org/forums/threads/lets-talk-about-primo-what-is-it-about-this-mysterious-compound-psl.90112/post-1357703 4. https://www.evolutionary.org/forums/threads/new-here-want-to-get-euro-pharmacies-lab-feedback.90352/post-1364797 5. https://www.evolutionary.org/forums/threads/new-to-steroids-help-please.99659/post-1549297 For 1-on-1 coaching/consultation/source help start conversation by contacting Stevesmi at: https://www.elitefitness.com/forum/members/stevesmi.219851/ or https://www.evolutionary.org/forums/members/stevesmi.85/ Where to get blood tests: https://www.evolutionary.org/forums/source-talk/bloodwork-private-md-5695.html Please note we're not doctors and the opinions are ours. It's our view and is based on our experience and views on the topic. Our Podcasts are for informational purposes and entertainment only. The Freedom of speech and 1st amendment applies.

Alexandra, JustTheInserts.comLike many, Alexandra was reluctant to heed warnings from friends and family.  And like many, vaccine injury got her attention.  How do we educate ourselves and fight the fear and arguments from authority? Alexandra has an answerIf you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-show Or you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7 Money should have intrinsic value AND transactional privacy: Go to DavidKnight.gold for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to TrendsJournal.com and enter the code KNIGHTBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.

Alexandra, JustTheInserts.comLike many, Alexandra was reluctant to heed warnings from friends and family.  And like many, vaccine injury got her attention.  How do we educate ourselves and fight the fear and arguments from authority? Alexandra has an answerIf you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-show Or you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7 Money should have intrinsic value AND transactional privacy: Go to DavidKnight.gold for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to TrendsJournal.com and enter the code KNIGHTBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-real-david-knight-show--5282736/support.

Send us a textDr. Jeremy Ayres, co-author of The Red Pill Revolution, passionately uncovers deception in the Medical Industrial Complex and its links to the Pharma and Food industries. Holding titles like Senior Practitioner of Physical Medicine and NaturoPractic Consultant, he merges Chiropractic, Osteopathy, and Naturopathy. Trained as a UK Osteopath, Jeremy, an International Natural Health Educator, guides numerous individuals toward natural healing. His mission involves blending Eastern wisdom with Western science, challenging medical manipulation, and advocating for holistic well-being to create a healthier world.John Gusty spent over 30 years in the entertainment industry working “behind the curtain” for some of music's biggest names, John turned his attention to health and wellness to help his wife heal from what was originally diagnosed as Multiple Sclerosis. He soon realized that the same deceit and profit motive that plagued the entertainment media was even worse inside the Medical Industry.As a champion of individuality, he now devotes his time to creating content that celebrates the spirit of sovereignty in all aspects of life.Find Dr. Jeremy Ayers and John Gusty at-https://naturallybetter4you.com/Find Boundless Body at- myboundlessbody.com Book a session with us here!

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Raman Sehgal, Founder & Global President at ramarketing & Host of Molecule to Market. For this milestone episode, your host is Molecule to Market's first guest from back in 2020, JoyL Silva, Customer Engagement Lead for the US Primary Care portfolio at Pfizer, who discusses the pharmaceutical and biotechnology supply chain with Raman Sehgal covering: Raman reflects on the podcast's evolution, from its inception during COVID-19 to becoming a globally recognized platform They discuss key trends in the pharma outsourcing sector and the impact of guests who have contributed to the podcast's success Raman shares highlights from his career, including the growth of his companies, ramarketing and Lead Candidate, and his private equity ventures Insights into balancing work and family life, with advice on being present and managing priorities A desert island question where Raman chooses which podcast guests he'd bring along, plus behind-the-scenes stories of challenges and humorous incidents JoyL Silva is the Customer Engagement Lead for Pfizer's US Primary Care portfolio, overseeing sales and account management across therapeutic areas such as Migraine, Cardiovascular, Anti-virals, and Vaccines. She leads high-performing teams that drive a $20B portfolio through agile methodologies and talent development. With over 20 years at Pfizer, JoyL has excelled in commercial leadership, business transformations, and operational expertise, delivering impactful results across multiple roles, including VP for Hematology and Biosimilars, General Manager of Pfizer CentreOne, and US/Global Commercial Lead for PAXLOVID, where she spearheaded global strategies and partnerships for Pfizer's COVID-19 antiviral therapeutic. JoyL frequently speaks at industry forums and contributes her expertise to various publications and professional boards, including the Pharma & Biopharma Outsourcing Association. Her accolades include being named to the Medicine Maker Power List and PharmaVOICE 100 Most Inspiring People in the Life Sciences Industry, as well as receiving awards such as the Scrip Best Partnership Alliance Award and Putnam Media Top 20 Influential Women in Manufacturing. Her career reflects a strong commitment to driving innovation and fostering leadership in the life sciences sector. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!    Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Good morning from Pharma and Biotech Daily, the podcast that gives you only what's important to hear in the Pharma and Biotech world.Roche has recently finalized a new deal in China valued at up to $1 billion for an antibody-drug conjugate. However, Neumora's depression drug trial has unfortunately not yielded successful results. Additionally, Sangamo has experienced a setback by losing a partnership with Pfizer in hemophilia gene therapy. On a more positive note, Axsome has released mixed data from Alzheimer's trials but still plans to move forward with filing for FDA approval.In other recent developments, Merck's PAH drug and BMS' Opdivo injection have received regulatory greenlights. It's important to note that there are currently job opportunities available in various pharmaceutical companies for those looking to make a career move in the industry.Looking ahead to 2024, the neurobiopharma industry has been characterized as a rollercoaster of ups and downs.

Nurses Out Loud – Ten years after the Ice Bucket Challenge raised $115 million for ALS, questions linger about how the funds were used. Nurses David, Jodi, and Nicole reveal how one drug company exploited charity money, marketed a failed drug, and charged patients $450 daily—all while regulators stood by, highlighting systemic corruption in health and pharmaceutical industries.

If you have zero clue what co-pay maximizers and/or co-pay accumulators are and the financial incentives involved for PBMs (pharmacy benefit managers) and plan sponsors here, after you're done listening to this episode, go back and listen to the show with Joey Dizenhouse (EP423). Also, the episode called “Game Theory Gone Wild” with Dea Belazi, PharmD, MPH (EP293). Both these shows could fill in some blanks. For a full transcript of this episode, click here. If you enjoy this podcast, be sure to subscribe to the free weekly newsletter to be a member of the Relentless Tribe. Here's the micro mini of the co-pay maximizer/accumulator deal. These are vehicles that are designed by vendors who are also sometimes called maximizers or sometimes they're also PBMs. But these programs are designed to get as much money out of Pharma as possible in the form of co-pay support. So, here's how the maximizers are supposed to maximize plan sponsors getting pharma money. Say, for some drug, the pharma company has, I don't know, $12,000 max in co-pay support available to patients in total per year. Pharma does always cap the dollars that are available for patients. So, in this hypothetical, $12k a year is available. What a forthright or well-run maximizer will do is figure out, you know, if there's $12k max available, then they'll set a co-pay—so there's variable co-pays for patients—so they'll set a patient co-pay of, like, $1000 a month, which adds up to $12k over 12 months of the year. Get it? Every single month, the patient has a $0 co-pay, but the plan maximizes the dollars that the plan gets. Or, you know, maybe they'll charge $1,025 a month so the patient has some small “skin in the game,” and the plan sponsor just banked $12k. Sounds great, right? Well, sure, when it works as promised … and we'll get to this in a moment. Accumulators, on the other hand, have no such “Hey, let's make sure the patient actually gets their meds” guardrails. They hear that the Pharma is offering $12k, and the accumulator vendor and their plan sponsor clients also are like, “Cool, let's get that money as fast as possible.” So, they make the co-pay for that drug, I don't know, like hypothetically $3000. Great, now the patient runs out of that co-pay money in May. And don't forget and/or let me inform you, for both maximizers and accumulators, dollars paid by the Pharma generally don't count to the plan deductible for the patient. So now, the patient walks into the pharmacy, if in an accumulator or in a poorly run maximizer program, they walk into the pharmacy in May and are told that if they want their drug, they're gonna need to pay the $3000 co-pay that was set out of pocket every month until they reach their deductible. With some of these co-pay maximizer/accumulator plans, the plan sponsor may be a little bit out of the loop relative to what is actually going on here. The plan sponsor may think that members are doing fine—you know, they're getting their drug every month—so they may be surprised to learn about this running out of money in May issue. And what is true more often than it's not true, this $3000 or whatever—hundreds or thousands of dollars—payment due co-pay, the patient learns about it at the pharmacy counter or while trying to get chemo. It comes as a complete surprise, the fact that they owe three grand or whatever. What patient just shrugs and pays up in that moment because they happen to have their entire deductible or thousands of dollars lying around and at the ready? What a shock to find this out at the pharmacy counter or at the infusion clinic. Some of these maximizer programs are also starting to veer back into accumulator zones, like they're doing things such as saying that the member must pay their out-of-pocket max or their deductible or 30% of the cost of the drug, right, like some number before the plan will allow the patient to use the co-pay reimbursement program to begin with. So, there's other things that are emerging right now, which, again, cause the patient to have a very, very large out of pocket in order for them to get a drug which they have been prescribed and—ostensibly, at least—need. Allegedly, and sometimes for sure, dollars raked in from Pharma make it across the PBM/maximizer, vendor, middleman trench all the way over to the plan sponsor. For sure, especially for the administrative only maximizer vendors … yeah, you're gonna have the dollars actually making it to the plan sponsor. But sometimes the vendor running these programs is paid spread, right? So, the more expensive the drug and the richer the co-pay card program, the more the vendor will make because they take a percentage of savings. So, the more expensive, the more savings, therefore, the more the vendor is gonna make. In these cases where the vendor is paid a spread, can I take Perverse Incentives for $600, Alex? Right? But in sum, again, there's a lot to this conversation with Bill Sarraille, so please do listen to the whole thing. Bill offers five main pieces of advice, so I'm just gonna cover them right here up front—spoiler alert, I guess, but just to keep them all in one place. 1. Look into what is going on with a maximizer and/or accumulator program. First of all, is the plan sponsor paying spread? And also, how are these programs being marketed to members and how aggressively? Because there are a lot of plan sponsors having way more negative impact than they suspect they are. So, that's point of advice #1: Really look into actually what is happening on the grounds with some of these programs. 2. Eliminate surprise. Any plan sponsor listening, and Brian Reid also says this very crisply in an episode a month or so ago (EP456). If a plan sponsor wants to do stuff like this—like force a patient to pay hundreds or thousands of dollars out of pocket—if at any point during the year they are gonna wind up with thousands of dollars in co-pay or coinsurance to get their Crohn's disease med or cancer med or whatever, be really up front about this at least. It's really important if we really want to make sure that patients are taking maintenance meds and getting the medications that they're prepared for the reality that, at a certain point during the year, they are going to have a really big bill. 3. There is legal risk here. So also, Bill's advice is check into whether accumulators and/or maximizers are unlawful under the ACA (Affordable Care Act) and/or by deceptive practices rules when maximizers or accumulators are teed up as a benefit. And it, again (reference point of advice #2), it's not explained that dollars they get from Pharma will be taken by the plan and not applied to the patient deductible. I was just reading about the crazy aggressive marketing tactics that some of these vendors are using to get members to sign up and … yeah, definitely look into deceptive practice rules. 4. If it's utilization management that we're trying to achieve here, then your utilization manager should be utilization managing. These maximizers are not meant to impact utilization management. Patients really cannot differentiate, as per study after study, it's very difficult for patients to differentiate high-value from low-value care or meds. So, pretty much the impact of having a patient with thousands or hundreds of dollars of out-of-pocket spend to get a med isn't going to be to ensure that the right people are taking the right med. Point is, use the right tool for the right job. So, if we're trying to keep patients away from low-value meds, the tool for that is utilization management. Also be aware, if the PBM says it cannot do utilization management or you'll lose your rebates and/or is pushing into a maximizer accumulator program to do this instead, that's kind of a clue that they cannot do it because they are taking money from Pharma to not have any restrictions on a drug. Read the article in the New York Times (you're welcome) about how PBMs took secret payments for the free flow of opioids, and Chris Crawford also talks about this sort of same-ish thing in an upcoming show relative to GLP-1s. But if you're trying to do utilization management, then do utilization management. 5. Use our understanding of this whole goings-on as a rationale or a way to tamp down perverse incentives. We want to wind up with patients getting charged a percentage of net prices, not a percentage of some wildly inflated list price with this whole accumulator maximizer contributing to, you know, just more wildly inflated list prices so the co-pay programs can be bigger and someone can make even more money off of the percentage of savings. And plan sponsors addicted to rebates now have another bucket of cash. Like, this is just another example of how perverse incentives pervade the system. And we should certainly be aware of that. Bill Sarraille was a healthcare attorney for many years. He retired from his law firm on the first of last year, and now he's doing the things he wanted to do before but couldn't because his billable rate was too high. Bill is teaching at the University of Maryland Law School and doing some regulatory consulting, etc. He's working with a variety of patient groups. Also mentioned in this episode are University of Maryland Francis King Carey School of Law; Joey Dizenhouse; Dea Belazi, PharmD, MPH; Brian Reid; Chris Crawford; Marilyn Bartlett; Scott Haas; Paul Holmes; and Tom Nash. You can learn more at University of Maryland Francis King Carey School of Law and by following Bill on LinkedIn. You can also sign up for his Substack.   Bill Sarraille is a professor of practice at the University of Maryland Francis King Carey School of Law, a regulatory consultant, and a retired senior member of the Healthcare Practice group at Sidley Austin LLP. Bill is a nationally recognized expert in healthcare, life sciences, drugs, medical devices, and patient access to treatments. He is widely known for his expertise in a broad array of healthcare matters, including rare disease treatment access barriers, pharmaceutical pricing, Anti-Kickback Law compliance, the 340B program, and managed care and PBM issues. During his years practicing law, Bill was recognized repeatedly by The Best Lawyers in America in both healthcare law and administrative law. He was also consistently listed as a leader in the field of healthcare law in Chambers USA: America's Leading Lawyers for Business. Bill also serves as the general counsel of the charity the Pharmaceutical Coalition for Patient Access, as an advisor to multiple patient advocacy groups on patient access issues, a compliance advisor to a coinsurance patient assistance foundation, and as the director of a rare disease society and Kalderos, Inc., a health IT firm with a focus on effectuating pharmaceutical discounts and rebates.   09:31 What should plan sponsors be aware of right now? 14:01 What is the justification for maximizers, and why is this at odds with the purpose of insurance? 18:05 Where does the issue of “fairness” land within cost containment? 20:00 Brian Reid's LinkedIn post on insurance company access challenges. 21:30 What are the real legal issues presented by some of these co-pay maximizers and co-pay accumulator programs? 27:06 How are these programs creating perverse incentives? 29:28 EP450 with Marilyn Bartlett, CPA, CGMA, CMA, CFM. 32:16 “If you're covered by the ACA, I think this is unlawful.” 32:57 What advice does Bill have in regard to these programs? 33:49 What potential litigations does Bill see coming in the near future in regard to these co-pay maximizers and co-pay accumulator programs? 38:38 EP365 with Scott Haas. 38:45 EP397 with Paul Holmes.   You can learn more at University of Maryland Francis King Carey School of Law and by following Bill on LinkedIn. You can also sign up for his Substack.   @HCLAWComment discusses #costcontainment on our #healthcarepodcast. #healthcare #podcast #pharma #healthcareleadership #healthcaretransformation #healthcareinnovation   Recent past interviews: Click a guest's name for their latest RHV episode! Stacey Richter (INBW41), Andreas Mang (Encore! EP419), Dr Komal Bajaj, Cynthia Fisher, Stacey Richter (INBW40), Mark Cuban and Ferrin Williams (Encore! EP418), Rob Andrews (Encore! EP415), Brian Reid, Dr Beau Raymond, Brendan Keeler  

Nurses Out Loud – Ten years after the Ice Bucket Challenge raised $115 million for ALS, questions linger about how the funds were used. Nurses David, Jodi, and Nicole reveal how one drug company exploited charity money, marketed a failed drug, and charged patients $450 daily—all while regulators stood by, highlighting systemic corruption in health and pharmaceutical industries.

In this Evolutionary.org Underground Podcast for iTunes episode your hosts Stevesmi and Da Mobster from the UK Iron Den discuss – Being supported in your bodybuilder journey by Euro Pharma • Why being supported makes your gym life so much easier • How helping others helps you! • Being supported in the gym • Types of external support and how to get yourself some • How Euro-Pharma listens to what YOU want from a source • Why Euro-Pharma is a highly regarded supplier of PEDS Link to articles: https://www.evolutionary.org/category/pc-bodybuilding/workouts/ Link to the Evolutionary threads discussing support and Euro Pharmacies 1. https://www.evolutionary.org/forums/threads/testosterone-equipoise-trenbolone-cycle-log.96963/post-1512809 2. https://www.evolutionary.org/forums/threads/evolutionary-org-hardcore-2-0-9-getting-ripped-in-the-spring-euro-pharmacies.88402/ 3. https://www.evolutionary.org/forums/threads/lets-talk-about-primo-what-is-it-about-this-mysterious-compound-psl.90112/post-1357703 4. https://www.evolutionary.org/forums/threads/new-here-want-to-get-euro-pharmacies-lab-feedback.90352/post-1364797 5. https://www.evolutionary.org/forums/threads/new-to-steroids-help-please.99659/post-1549297 For 1-on-1 coaching/consultation/source help start conversation by contacting Stevesmi at: https://www.elitefitness.com/forum/members/stevesmi.219851/ or https://www.evolutionary.org/forums/members/stevesmi.85/ Where to get blood tests: https://www.evolutionary.org/forums/source-talk/bloodwork-private-md-5695.html Please note we're not doctors and the opinions are ours. It's our view and is based on our experience and views on the topic. Our Podcasts are for informational purposes and entertainment only. The Freedom of speech and 1st amendment applies.

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.##News 1: Pfizer announces positive results from COVID-19 vaccine trialPfizer has announced positive results from its phase 3 trial of a COVID-19 vaccine. The vaccine was found to be over 90% effective in preventing the virus. This is a significant milestone in the fight against the pandemic.##News 2: Moderna's COVID-19 vaccine shows promising resultsModerna has also reported promising results from its COVID-19 vaccine trial. The vaccine was found to be over 94% effective in preventing the virus. This is another positive development in the race to find a safe and effective vaccine.##News 3: Novartis receives FDA approval for new cancer treatmentNovartis has received FDA approval for a new cancer treatment. The treatment is a targeted therapy that has shown promising results in clinical trials. This approval provides new hope for patients with certain types of cancer.##News 4: Roche launches new diagnostic test for Alzheimer's diseaseRoche has launched a new diagnostic test for Alzheimer's disease. The test is designed to detect biomarkers associated with the disease, allowing for earlier diagnosis and treatment. This could have a significant impact on patient outcomes.##News 5: Johnson & Johnson announces breakthrough in HIV vaccine researchJohnson & Johnson has announced a breakthrough in HIV vaccine research. The company has developed a mosaic-based vaccine that has shown promising results in early-stage clinical trials. This could be a major step forward in the fight against HIV.##News 6: AstraZeneca partners with Oxford University on COVID-19 treatmentAstraZeneca has partnered with Oxford University on a potential COVID-19 treatment. The treatment is an antibody cocktail that has shown positive results in early trials. This collaboration could help accelerate the development of much-needed treatments for the virus.##Thank you for listening to Pharma and Biotech Daily. Stay tuned for more updates on the latest news and developments in the industry.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.##FDA Approves New Drug for Alzheimer's DiseaseThe FDA has recently approved a new drug for the treatment of Alzheimer's disease. This drug has shown promising results in clinical trials, with patients experiencing a significant improvement in cognitive function. This is a major breakthrough in the treatment of Alzheimer's, as there have been few advancements in this area in recent years. The approval of this new drug is expected to have a significant impact on the lives of those suffering from this devastating disease.##Major Pharmaceutical Company Announces MergerA major pharmaceutical company has announced plans to merge with another leading company in the industry. This merger is expected to create a powerhouse in the pharmaceutical world, with combined resources and expertise that will drive innovation and growth. The new company is set to become a major player in the global pharmaceutical market, with a strong presence in key therapeutic areas. This merger is a significant development in the industry and is expected to have a major impact on the competitive landscape.##Breakthrough in Cancer Treatment ResearchResearchers have made a significant breakthrough in the field of cancer treatment. A new therapy has been developed that has shown promising results in clinical trials, with patients experiencing a significant reduction in tumor size and improved survival rates. This breakthrough has the potential to revolutionize the way cancer is treated, offering new hope to patients around the world. The research team behind this therapy is now working towards gaining FDA approval, with hopes of bringing this groundbreaking treatment to market in the near future.##Global Vaccine Distribution EffortsEfforts are underway to distribute COVID-19 vaccines to countries around the world, with a focus on ensuring equitable access for all populations. Global organizations and governments are working together to overcome logistical challenges and ensure that vaccines reach those who need them most. This global vaccine distribution effort is crucial in the fight against the pandemic, and will play a key role in achieving herd immunity and bringing an end to the crisis. The success of these distribution efforts will depend on collaboration and coordination at an international level, with the goal of reaching as many people as possible in a timely manner.##New Drug Shows Promise in Treating Rare DiseaseA new drug has shown promise in treating a rare genetic disease that affects a small number of patients worldwide. Clinical trials have demonstrated that this drug can effectively target the underlying cause of the disease, leading to improvements in symptoms and quality of life for patients. This breakthrough offers hope to those suffering from rare diseases, providing a potential treatment option where none existed before. The research team behind this drug is now working towards gaining regulatory approval, with plans to make it available to patients in the near future.##Innovations in Gene TherapyAdvancements in gene therapy are opening up new possibilities for treating a wide range of genetic disorders. Researchers are developing innovative gene editing techniques that can target specific genes and correct mutations that cause disease. These advancements have the potential to revolutionize the treatment of genetic disorders, offering hope to patients who previously had limited options for treatment. The field of gene therapy is rapidly evolving, with new breakthroughs being made on a regular basis. The future looks bright for gene therapy, with the potential to transform the lives of patients around the world.##That's all for today's episode of Pharma and Biotech Daily. Stay tuned for more updates on the latest developments in the pharmaceutical and biotechnology industries.

Kurt Havens is an expert in bodybuilding pharmacology, training, nutrition, PED's, and the science of building musclePlease share this episode if you liked it. To support the podcast, the best cost-free way is to subscribe and please rate the podcast 5* wherever you find your podcasts. Thanks for watching.To be part of any Q&A, follow trensparentpodcast or nylenayga on instagram and watch for Q&A prompts on the story  https://www.instagram.com/trensparentpodcast/Watch The Podcast:https://www.youtube.com/channel/UCqgN2kieCEHwZ9M-QFBxfCgPharma TRT, GH analogs, peptides, IGF-1, var troche, fat-loss/hair-loss treatments, etc | HRT Men's Health Optimization: https://transcendcompany.com/patient-intake-form/?ls=Nyle+NaygaHuge Supplements (Protein, Pre, Defend Cycle Support, Utilize GDA, Vital, Astragalus, Citrus Bergamot): https://www.hugesupplements.com/discount/NYLESupport code 'NYLE' 10% off - proceeds go towards upgrading content productionYoungLA Clothes: https://www.youngla.com/discount/nyleCode ‘NYLE' to support the podcastLet's chat about the Podcast:Instagram: https://www.instagram.com/trensparentpodcast/TikTok: https://www.tiktok.com/@transparentpodcastPersonalized Bodybuilding Program:  https://www.nylenaygafitness.comTimestamps: 00:00:00 - Teaser & Intro00:01:04 - Bodybuilding & having kids00:04:49 - is insulin responsible for obesity? 00:06:41 - Thoughts on sugar consumption00:10:57 - what's your ideal training regimen & style?00:14:53 - Thoughts on the differences between Myofibrillar & Sarcoplasm00:27:46 - Science-based vs bro science00:46:10 - Can using more drugs now may lead to needing more later?00:55:40 - What are the consequences of misusing drugs at a young age?00:57:18 - How does GH affect sleep cycles?01:13:20 - GH myths01:37:46 - how to mitigate the side effects of gear?01:38:40 - breaks for cruising GH01:40:02 - Pharma grade GH vs Underground GH01:42:15 - Oral timing01:44:04 - Peptide risks01:46:51 - Last question

 The league has released the 2025 schedule and has given some insight surrounding GAM. Also, a fan favorite is going back to where it all began. Happy Holidays and thanks for listening!

Stock market update for December 31, 2024. Follow our new Instagram account ⁠@TheRundownDaily

In this Evolutionary.org Underground Podcast for iTunes episode your hosts Stevesmi and Da Mobster from the UK Iron Den discuss - Benefits of Evolutionary.org vs. social media for bodybuilding by Geneza Pharma • Why some social media information is just plain wrong • Some examples of social media scams and cons • How Evolutionary.org literally has highly qualified and regarded help on tap • Other examples of why Evolutionary.org is a must for proper help and assistance • Why Geneza Pharma wants you to succeed too Link to articles: https://www.evolutionary.org/steroids-questions-answers/ Link to Evo threads discussing reddit etc: 1. https://www.evolutionary.org/forums/threads/dadbod-to-roman-god-trt-primobolan-and-anavar-log.101799/post-1652656 2. https://www.evolutionary.org/forums/threads/heavy-oral-cycle-of-sarms-aas.99552/post-1544084 3. https://www.evolutionary.org/forums/threads/canadian-source-emeritus-pharmaceuticals.98802/post-1560953 4. https://www.evolutionary.org/forums/threads/ultimate-performance-labs-aussie.101179/post-1611227 5. https://www.evolutionary.org/forums/threads/is-combining-proviron-and-clomid-a-good-way-to-boost-testosterone-levels.97952/post-1479094 For 1-on-1 coaching/consultation/source help start conversation by contacting Stevesmi at: https://www.elitefitness.com/forum/members/stevesmi.219851/ or https://www.evolutionary.org/forums/members/stevesmi.85/ Where to get blood tests: https://www.evolutionary.org/forums/source-talk/bloodwork-private-md-5695.html Please note we're not doctors and the opinions are ours. It's our view and is based on our experience and views on the topic. Our Podcasts are for informational purposes and entertainment only. The Freedom of speech and 1st amendment applies.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. ## Pfizer announces positive results for COVID-19 vaccinePfizer has announced positive results for its COVID-19 vaccine, with an efficacy rate of over 90%. This is a significant development in the fight against the pandemic, as it could potentially lead to widespread vaccination and a return to normalcy. ## Moderna receives FDA emergency use authorization for COVID-19 vaccineModerna has received emergency use authorization from the FDA for its COVID-19 vaccine. This is another important step in the fight against the pandemic, as it will allow for the vaccine to be distributed more widely and help to protect more people from the virus. ## Johnson & Johnson applies for emergency use authorization for COVID-19 vaccineJohnson & Johnson has applied for emergency use authorization from the FDA for its COVID-19 vaccine. If approved, this vaccine could provide another option for individuals looking to protect themselves from the virus. ## AstraZeneca faces scrutiny over COVID-19 vaccine dataAstraZeneca is facing scrutiny over the data from its COVID-19 vaccine trials. Questions have been raised about the efficacy of the vaccine, as well as potential safety concerns. This is a reminder of the importance of transparency and thorough evaluation in the development of vaccines. ## Novavax announces positive results for COVID-19 vaccineNovavax has announced positive results for its COVID-19 vaccine, with an efficacy rate of over 85%. This is another promising development in the fight against the pandemic, as it could provide yet another option for vaccination. ## ConclusionIn conclusion, there have been several significant developments in the world of COVID-19 vaccines. From positive results to emergency use authorizations, these updates are a testament to the hard work and dedication of researchers and scientists around the world. As we continue to navigate this challenging time, it is important to stay informed and vigilant in our efforts to combat the pandemic.

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. ##News 1: Pfizer announces positive results for new cancer drugPfizer has recently announced positive results from a phase 3 clinical trial for their new cancer drug. The drug showed a significant increase in overall survival rates compared to standard treatments. This is great news for patients with this type of cancer and could potentially lead to a new treatment option in the near future.##News 2: FDA approves new gene therapy for rare genetic disorderThe FDA has approved a new gene therapy for a rare genetic disorder that affects children. This therapy has shown promising results in clinical trials, with patients experiencing significant improvements in their symptoms. This approval marks a major milestone in the field of gene therapy and provides hope for patients with rare genetic disorders.##News 3: Biogen announces breakthrough Alzheimer's drugBiogen has announced a breakthrough in the treatment of Alzheimer's disease with their new drug. The drug has shown to significantly slow the progression of the disease in clinical trials, offering hope to millions of patients and their families. This development could potentially change the landscape of Alzheimer's treatment moving forward.##News 4: Moderna ramps up production of COVID-19 vaccineModerna has announced plans to ramp up production of their COVID-19 vaccine in order to meet global demand. The company has already distributed millions of doses worldwide, with plans to increase production even further in the coming months. This is a positive step towards achieving widespread vaccination and controlling the spread of the virus.##News 5: Novartis partners with research institute on new drug discoveryNovartis has entered into a partnership with a leading research institute to collaborate on new drug discovery efforts. This collaboration brings together expertise from both organizations to accelerate the development of innovative therapies for patients. The partnership highlights the importance of collaboration in driving scientific advancements in the pharmaceutical industry.

On Friday's Mark Levin Show, Rich Valdes, host of America At Night, fills in for Mark. New York City has not changed when it comes to the increase of illegal aliens committing severe crimes, making any part of NYC unsafe. The fact that an illegal alien burned a woman to death while raiding the subway train is out of control. The scariest thing is that Mayor Eric Adams and Gov. Kathy Hochul seem to do nothing about this and now are trying to back pedal on making NYC a sanctuary city. Border Czar Tom Homan expresses his frustration towards those who are against ICE and are against making illegal criminals accountable for the crimes they commit, let alone be in our country Illegally. In addition, President Biden and Kamala Harris have destroyed this country and then you have people like Julian Castro claiming that it is inhumane and immoral to deport illegal aliens. Also, the healthcare industry is coming up with more ways to cheat the responsibility we have to make sure we are healthy mentally and physically active. Instead, the left pushes for more pharma and offer Ozempic or Mounjaro instead of providing healthier options that encourages you to decide for your health not drugs like RFK suggests. This is another plan for the left and big Pharma to keep the American people in a cycle that makes them pay for drugs, making them depend on the government and pharma. Learn more about your ad choices. Visit podcastchoices.com/adchoices

All Home Care Matters and our host, Lance A. Slatton welcome Katie Kristofic founder of The Carefullist back as guest to the show.   About Katie Kristofic:   An entrepreneurial spirit, Katie Kristofic has always been drawn to companies and projects with a greater purpose. She founded The Carefullist in 2023, providing an online social community, resources, and support for family caregivers after her caregiving journey ended when her mom passed away from Alzheimer's Disease.   Katie has over 20 years of marketing communications experience, including 15 years in Pharma and Biotech leading teams in strategic and promotional marketing, public relations, and crisis communications management. Katie previously held sales and regional account management positions with medical book and supply distribution companies. She has a BA in Communication Studies from West Chester University and a Corporate Communications Certification from Cornell University. In addition to her passion for leveling the caregiving playing field, Katie enjoys comedy, baking, and spending time with her family.   About The Carefullist:   Caring for a family member is the ultimate act of love. We know, we've been there. It can also be challenging and lonely. We've been there, too. As a matter of fact, that's how The Carefullist began. As the saying goes, when there is a diagnosis there are actually two new patients; the person receiving care and the person giving it.   We share carefully vetted caregiving resources and tips, in addition to personal takes on grief, how that process often starts far before a loved one passes away, and how grief can occur with any life-altering change. Everyone who finds themselves in the role of caregiver, as someone else's “person”, deserves to have somewhere to turn that makes the journey go just a little bit smoother, feel a little less daunting, and hopefully, a lot less lonely.   We imagine a time when the resources and support family caregivers need are not only at their fingertips, but also found easily and come strongly recommended by trusted Carefullists who have walked this path before.

Who are the power players surrounding President Trump as he assembles his inner circle? There are MANY but two names have become prominent and today we will scrutinize Susie Wiles, the newly appointed Chief of Staff and Calley Means, a heavily connected Washington DC insider, former PHARMA lobbyist and apparently the head of the new #MAHA Movement.We will also look at the organizations linked to them who are promoting big government, globalist agenda items. Organizations like the lobbying firms, Mercury LLC & Ballard Partners (linked to Wiles) and also the Rockefeller Foundation and the Council on Foreign Relations (linked to the Means family).Is our country being run by our elected leaders? Or simply the highest bidders?We begin to ask the hard questions today on the Shannon Joy Show.

Matt Gaetz Key Witness Demands RETRACTION of Ethics Smear (RETRACT THIS NOW!)Liberals BEG Democrat Congress to STOP Trump Taking Office (THAT'S INSURRECTION!!)Luigi Mangione's Judge IN BED with BIG PHARMA (THAT'S A CONFLICT!)Alleged shoplifters SHOCKED by stricter California laws | Criminal Lawyer REACTS ('THEY DON'T PLAY')

REVIVE – heal your body from the inside out. Visit https://mybrightcore.com/andweknow and get 25% off with code: AWK Or call (888) 317-9941) for up to 50% off!  ——— Hunter's Blend Coffee: https://www.huntersblendcoffee.com/?ref=AWK ———— AT SEA with LT cruise: https://www.inspirationtravel.com/Ita ————————— Protect your investments with And We Know http://andweknow.com/gold Or call 720-605-3900, Tell them “LT” sent you. ————————————————— *Our AWK Website: https://www.andweknow.com/ *The Patriot Light: https://thepatriotlight.com/ ➜ AWK Shirts and gifts: https://shop.andweknow.com/ *BOWLING BROS: Sons Bowling channel: https://www.youtube.com/@Bowling_Bros/videos ————————————————— Trump posts same video at 5:29 on Truth and 5:46 on X exactly 17 min apart. https://x.com/5Never_Give_Up5/status/1872064035916808415 Kamala Harris identified as Indian until in 2020 she realized it was more politically beneficial to be black https://x.com/Ravious101/status/1872025537897771248 On the eve of Orthodox Christmas, Ukraine's state television aired a disturbing video showing Ukrainians dressed as demons and devils https://x.com/Megatron_ron/status/1872073974869573955 Pray for these babies….https://x.com/ReturnOfKappy/status/1872061655670280404 EZRA COHEN CRUMBS https://x.com/GH17TAFKAG/status/1872018748292415540 Trump just posted this. It should be in the Hall of Fame. This is literally Trump at his best https://x.com/MAGAVoice/status/1872010905376194598 ormer Clinton adviser and Former California State Senator warns that the Democrat party is on the verge of collapse: https://x.com/EricAbbenante/status/1871683771529068552 —— *DONATIONS SITE: https://bit.ly/2Lgdrh5   *Mail your gift to: And We Know 30650 Rancho California Rd STE D406-123 (or D406-126) Temecula, CA 92591   ➜ AWK Shirts and gifts: https://shop.andweknow.com/   ➜ And We Know Challenge Coins & Patriot Pins https://andweknow.com/ThePatriotPin/   ➜ Audio Bible https://www.biblegateway.com/audio/mclean/kjv/1John.3.16   Connect with us in the following ways: + DISCORD Fellows: https://discord.gg/kMt8R2FC4z

Find my Dilbert 2025 Calendar at: https://dilbert.com/ God's Debris: The Complete Works, Amazon https://tinyurl.com/GodsDebrisCompleteWorks Find my "extra" content on Locals: https://ScottAdams.Locals.com Content: Politics, Tylenol, Ozone Hole, Mystery Orb Drones, Nancy Mace, Nuclear Power Need, RFK Jr., Pharma TV Ads Ban, Pharma's Censorship Power, Elon Musk, Ozempic Santa, Democrat Election Loss Confusion, Democrat Top-Down Brainwashing, J6 Fed Provoked Poll, Fed Jobs Reporting Errors, Foreign Tech Worker Hiring, Comprehending Superior Intelligence, Indiana University, Azerbaijan Plane Crash, Border Wall Sale Paused, Ukrainian Drone Production, RFK's Fauci Book, Pfizer Vaccine Data, Scott Adams ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ If you would like to enjoy this same content plus bonus content from Scott Adams, including micro-lessons on lots of useful topics to build your talent stack, please see scottadams.locals.com for full access to that secret treasure. --- Support this podcast: https://podcasters.spotify.com/pod/show/scott-adams00/support

Watch this episode uncensored & ad-free on Patreon: https://patreon.com/dannyjones Calley Means is a former food lobbyist, Dr. Jack Kruse is a neurosurgeon & Dr. Mary Bowden is a board certified otolaryngologist specializing in respiratory illness.  SPONSORS https://bit.ly/viiadannyjones - Try VIIA & use code DANNY https://whiterabbitenergy.com/?ref=DJP - Use code DJP for 20% off EPISODE LINKS Mary Bowden: https://x.com/MdBreathe Calley Means: https://x.com/calleymeans Jack Kruse: https://x.com/DrJackKruse FOLLOW DANNY JONES https://www.instagram.com/dannyjones https://twitter.com/jonesdanny OUTLINE 00:00:00 - Public health crisis 00:09:59 - Calling for a ban on pharma products 00:21:53 - Jack's medical freedom law 00:30:31 - Calley Means work history 00:46:14 - Food vs Pharma 00:49:35 - Mary Bowden's medical background 00:59:20 - Jack's experience with ICU patients 01:00:28 - Jack on Calley's mom & pancreatic cancer 01:11:29 - Missing death certificate 01:17:47 - Bobby Kennedy & his threat to biotechnology 01:25:26 - Hidden Agendas 01:29:32 - Censorship 01:31:46 - Council of Foreign Relations 01:33:41 - MK-ULTRA 01:36:25 - World Economic Forum 01:44:50 - Jack's problem w/ Joe Rogan, Andrew Huberman & Tucker Carlson 01:47:40 - Trump, Kennedy & the health state of emergency 01:52:23 - Why Jack no longer supports RFK Jr. 01:59:28 - Health propaganda 02:03:16 - How Jack would reform health in the US 02:19:55 - Calley's link to Trump & Kennedy 02:22:22 - Lobbyists are already subverting RFK Jr. 02:29:23 - Calley's personal opinion on mandates 02:40:51 - Strategy for making change 02:53:54 - Jacks problem with Calley 02:59:46 - DNA plasmids & SV40 promoter 03:03:46 - Calley's commitment Learn more about your ad choices. Visit megaphone.fm/adchoices